	US 11,993,613 B2
	Thiazolo[5,4-b]pyridine MALT-1 inhibitors
Puneet Kumar, Santa Clara, CA (US); Anthony Mastracchio, Libertyville, IL (US); Mark Mills, Nottingham (GB); and Andrew William Phillips, Nottingham (GB)
Assigned to AbbVie Inc., North Chicago, IL (US)
Filed by AbbVie Inc., North Chicago, IL (US)
Filed on Mar. 30, 2023, as Appl. No. 18/192,810.
Claims priority of provisional application 63/362,302, filed on Mar. 31, 2022.
Prior Publication US 2023/0312601 A1, Oct. 5, 2023
Int. Cl. A61P 35/00 (2006.01); C07D 513/04 (2006.01)

CPC C07D 513/04 (2013.01) [A61P 35/00 (2018.01)]

2 Claims

1. N-{(1S)-1-[4-({7-[(1R)-2,2-difluoro-1-methoxyethyl]-2-methyl[1,3]thiazolo[5,4-b]pyridin-6-yl}amino)phenyl]-2,2,2-trifluoroethyl}-N-methyl-1,1-dioxo-1λ⁶-thiane-4-carboxamide; or a pharmaceutically acceptable salt thereof.